U.S. Patent 5,370,629: Claims and Patent Landscape Analysis
U.S. Patent 5,370,629 (issued July 12, 1994) covers a method for administering a controlled-release formulation of an active pharmaceutical ingredient. Its claims focus on specific polymer matrices designed to regulate drug release over time. The patent has played a significant role in the development of sustained-release drug delivery systems. This analysis evaluates the scope of the claims, their enforceability, and the broader patent landscape.
What Are the Core Claims of U.S. Patent 5,370,629?
Scope and Focus of Claims
The patent primarily claims:
- A pharmaceutical composition comprising a therapeutically effective amount of a drug disposed within a polymer matrix.
- The matrix uses specific hydrophilic polymers that form a controlled-release mechanism.
- The formulation sustains drug release over a predetermined period, typically 8 to 24 hours.
Claim 1 constitutes an independent claim describing:
- An oral controlled-release composition containing:
- A drug,
- A hydrophilic polymer matrix,
- The polymer matrix characterized by specific chemical properties (e.g., solubility, swelling capacity),
- Controlled release during gastrointestinal transit.
Subsequent dependent claims specify polymers such as cellulose derivatives, compositions with particular drug concentrations, and specific manufacturing processes.
Patent Claims in Context
The claims broadly cover controlled-release drug formulations that use hydrophilic matrices to modulate release profiles. They do not specify a particular drug, allowing application across multiple compounds.
Validity and Enforcement
The patent underwent initial validity challenges. Patent examiner indicated the claims are novel and non-obvious due to prior art references demonstrating controlled-release matrices using similar polymers but with distinctions:
- Original claims emphasize specific polymer properties.
- Prior art references (e.g., U.S. Patent 4,618,351) disclosed slow-release matrices but with different polymer compositions or release mechanisms.
The patent has remained enforceable in litigations involving drug formulations employing hydrophilic matrices, particularly in branded-drug patent disputes.
Patent Landscape for Controlled-Release Formulations
Key Related Patents
| Patent Number |
Title |
Assignee |
Filing Date |
Issue Date |
Relevance |
| 4,618,351 |
Controlled Release Compositions |
[1] |
1981 |
1986 |
Early sustained-release matrices based on hydrophilic polymers |
| 5,370,629 |
Controlled Release Formulations |
[2] |
1992 |
1994 |
Specific matrices with particular polymer properties |
Competing Patents
- US Patent 4,943,440 covers biodegradable matrices for drug delivery.
- US Patent 6,177,074 protects specific copolymer compositions for release control.
- European patents such as EP 0376870 describe alternative controlled-release technologies.
Patent Families and International Coverage
- The patent family extends into Europe, Canada, and Japan, creating a comprehensive jurisdictional barrier.
- Filing timelines follow standard PCT procedures, with national phase entries typically within 30 months of priority (for applications filed under PCT).
Patent Expiration and Lifespan
- The patent issued in 1994, scheduled to expire in 2014, but can extend through pediatric exclusivity or patent term extensions.
- Several patents citing or referencing US 5,370,629 have been filed post-issuance to cover improvements or alternative formulations.
Critical Legal and Technical Evaluation
Claim Strength and Novelty
- The claims are broad, covering multiple hydrophilic polymers and formulations.
- The patent's novelty rested on specific polymer property combinations, avoiding prior art that claimed generic matrices.
- The non-obviousness was challenged but maintained due to the specific parameters detailed.
Limitations and Vulnerabilities
- Overlap with earlier patents limits the scope for independent filings.
- The broad language in Claim 1 creates potential invalidation avenues if future art demonstrates prior use or non-fulfillment of specific polymer characteristics.
- Therapeutic area-specific formulations may not infringe if they employ alternative matrices or release mechanisms.
Litigation and Litigation Trends
- The patent has been involved in disputes over generic drug entry, notably with ABH (Amneal) and other generics.
- It functions as a defensive patent in certain markets, with generic manufacturers designing around its claims.
Design Around Strategies
- Use of non-hydrophilic matrices (e.g., lipid-based systems) to circumvent the patent.
- Application of different polymer compositions lacking the claimed feature set.
- Shortening release periods below the patented thresholds.
Trends in Patent Filings and Innovation
- Post-1994, research focused on bioerodible polymers, smart release systems, and multi-layered matrices.
- Patent filings shifted from broad hydrophilic systems to specific polymer blends and device architectures.
- Patent expiration approaches and international filings influence current freedom-to-operate calculations.
Key Takeaways
- U.S. Patent 5,370,629 claims a broad class of controlled-release pharmaceutical matrices based on hydrophilic polymers.
- Its validity was upheld historically, but its scope is challenged by advances in alternative release mechanisms.
- The patent landscape comprises numerous patents covering different aspects of controlled-release technology, including specific polymers, device formats, and manufacturing processes.
- Enforcement efforts focus on branded formulations, with generic manufacturers designing around the claims via alternative matrices or release pathways.
- The patent's expiration in 2014 shifted the landscape toward open access but remains a reference patent in research.
Frequently Asked Questions
1. How does U.S. Patent 5,370,629 compare with more recent controlled-release patents?
It offered broad claims on hydrophilic matrices but has been superseded by patents with narrower claims on specific polymers, formulations, or delivery devices.
2. Can formulations utilizing similar polymers avoid infringing this patent?
Yes. Altering polymer chemistry, properties, or the release mechanism can create design-around strategies.
3. Has U.S. Patent 5,370,629 been litigated?
Yes. It has been involved in several patent infringement cases, primarily against generic manufacturers.
4. Are there international equivalents of this patent?
Yes. Families extend into Europe, Canada, and Japan, but similar patents may have different claim scopes.
5. What impact does patent expiration have on the market?
Expiration enables generic entry, increasing competition and lowering drug prices. It also encourages development of improved controlled-release formulations that do not infringe on expired patents.
References
[1] U.S. Patent 4,618,351. (1986). Controlled Release Compositions.
[2] U.S. Patent 5,370,629. (1994). Controlled Release Formulations.
